Billerica, MA, September 13, 2016 – ProterixBio, Inc. today announced that it has joined the Industrial Advisory boards of the COPD (chronic obstructive pulmonary disease) Foundation and the SPIROMICS Consortium. Joining both advisory boards reflects ProterixBio’s commitment to develop novel clinical applications including diagnostics products and disease management tools for pulmonary diseases.
ProterixBio is developing innovative products to transform the management of chronic diseases, with the initial applications focusing on pulmonary diseases such as COPD, cystic fibrosis and idiopathic pulmonary fibrosis (IPF). COPD – which affects over 12+ million people in the US alone – impacts the productivity and quality of life of millions of individuals and represent a significant portion of global health care spending.
The Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS) is a joint National Institutes of Health (NIH) and industry funded multi-center study of COPD patients designed to guide the future development of therapies for COPD. The SPIROMICS study seeks to classify COPD patients into molecularly and clinically defined groups most likely to benefit from a given therapy during a clinical trial as well as identify biomarkers and endotypes that can be used as intermediate outcomes to reliably predict clinical benefit during therapeutic trials and ultimately may lead to more individualized treatment. The SPIROMICS study was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award number HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C HHSN268200900019C, HHSN268200900020C.
The COPD Foundation is the only non-governmental agency based in the United States devoted solely to chronic obstructive pulmonary disease (COPD) and was established to undertake initiatives that result in expanded services for those with COPD and to improve the lives of individuals affected by COPD. The Foundation focuses on achieving these results through research, education and advocacy programs while serving as an intermediary to fund and coordinate a number of major public-private clinical studies, including SPIROMICS.
“ProterixBio seeks to positively impact COPD care by integrating novel bioclinical biomarker tests with supporting disease management tools,” said Grace E. Colon, Ph.D., president and chief executive officer of ProterixBio. “Joining the industrial advisory boards of the leading organization whose mission aligns with ProterixBio’s, and one of the largest NIH-sponsored clinical studies working to define COPD subgroups, will help us efficiently design our clinical studies and collaborate closely with all the relevant stakeholders in academia and industry.”
“The COPD Foundation is proud to be working with ProterixBio to develop the next generation of disease management approaches,” said Craig Kephart, CEO of the COPD Foundation. “The COPD Foundation is dedicated to improving the lives of all those affected by COPD and we are grateful to ProterixBio for their generous sponsorship which will enable us to help the research and patient community alike.”
About the COPD Foundation
The COPD Foundation’s mission is to prevent and cure chronic obstructive pulmonary disease and improve the lives of all people affected by COPD. The Foundation’s activities focus on achieving these results through research, education and advocacy programs. To learn more or get involved, call the C.O.P.D. Information Line at 1-866-316-COPD (2673) or visit www.copdfoundation.org. To become a member of our community visit www.copd360social.org and join the conversation.
ProterixBio develops and commercializes disease management solutions that integrate novel bioclinical analytics with digital tools to improve the effectiveness and efficiency of chronic disease care. The company is dedicated to leveraging its innovative approach and differentiated expertise to build transformative disease management platforms. ProterixBio’s initial focus is on pulmonary diseases such as COPD (chronic obstructive pulmonary disease), which affects more than 12 million Americans. ProterixBio is headquartered in Billerica, Mass. For additional information, please visit www.proterixbio.com.
The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.